SCHEMBL20224059

SCHEMBL20224059

CCOC(=O)n1ccc2c(F)c(OC(C)(C)C)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ LPO P22079 4/20 0.35
▸ LMNA P02545 3/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ ELANE P08246 5/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ KMT2A Q03164 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP4F2 P78329 1/20 0.33
▸ CYP4A11 Q02928 1/20 0.33
▸ ABCB11 O95342 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ PMP22 Q01453 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ MAPK11 Q15759 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32
▸ FBP1 P09467 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20224070 0.91 ELANE (0.33) L3MBTL1ELANENOTUMKMT2AALDH1A1
SCHEMBL20224053 0.87 MEN1 (0.36) LPONOTUMKMT2A
SCHEMBL20224102 0.86 NOTUM (0.43) L3MBTL1LPOLMNACYP1A2ELANE
SCHEMBL18054331 0.85 NPSR1 (0.39) L3MBTL1LPOLMNACYP1A2ELANE
SCHEMBL18052970 0.85 ALDH1A1 (0.39) LPOLMNACYP1A2ELANEPOLB
SCHEMBL20224065 0.84 NOTUM (0.50) NOTUMALDH1A1
SCHEMBL20224103 0.84 NOTUM (0.33) NOTUM
SCHEMBL20224104 0.80 LPO (0.35) L3MBTL1LPOLMNACYP1A2KMT2A
SCHEMBL20224097 0.80 L3MBTL1 (0.34) L3MBTL1LPOLMNACYP1A2ELANE
SCHEMBL18054133 0.79 ELANE (0.34) LPOLMNACYP1A2ELANENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766879-B2 Pyrimidine derivatives as kinase inhibitors and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2020-09-08 — — US disclosed
US-20180215734-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. 2018-08-02 — — US disclosed
US-20180215734-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. 2018-08-02 — — US disclosed
US-20180155327-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. 2018-06-07 — — US disclosed
US-20180155327-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. 2018-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215734-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS DCK, TK1, DTYMK L3MBTL1 2715/4885LPO 4866/4885LMNA 3473/4885
US-10766879-B2 Pyrimidine derivatives as kinase inhibitors and their therapeutical applications DCK, TK1, DTYMK L3MBTL1 2644/4885LPO 4844/4885LMNA 3575/4885
US-20180155327-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS DCK, TK1, DTYMK L3MBTL1 2644/4885LPO 4844/4885LMNA 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback